THEOPHYLLINE
Generic: THEOPHYLLINE
Ajanta Pharma USA Inc.Manufacturer
ORALRoute
THEOPHYLLINE ANHYDROUSActive Substance
2025-01-13Original Approval
THEOPHYLLINE is FDA application ANDA218401, sponsored by AJANTA PHARMA LTD. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2025-05-15
Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark PhOOS results reported for the Dissolution (by UV) test.
Class II2025-08-08
Theophylline extended-release tablets 400mg, 100-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals LimiteFailed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV)
Class II2021-03-15
Theophylline (Anhydrous) Extended-Release Tablets 400 mg 100 Tablets Rx Only NDC 68462-380-01 Manufactured by: Glenmark CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Top Reported Reactions
1
DYSPNOEA
2,461 reports
2
ASTHMA
2,128 reports
3
PNEUMONIA
1,492 reports
4
WHEEZING
1,458 reports
5
VOMITING
1,266 reports
6
COUGH
1,128 reports
7
DRUG HYPERSENSITIVITY
990 reports
8
MALAISE
837 reports
9
OEDEMA
815 reports
10
DRUG INEFFECTIVE
807 reports